Farah Louise Lim

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study

Melissa L. Johnson, Byoung Chul Cho, Alexander Luft et al. · Journal of Clinical Oncology · 2022 · 434 citations · Full text

Medicine, Oncology, Pharmacology +17

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

Luis Paz‐Ares, Óscar Juan, Giannis Mountzios et al. · Journal of Clinical Oncology · 2024 · 115 citations · Full text

Medicine, Oncology, Pharmacology +17

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Hossein Borghaei, Filippo de Marinis, Daphne W. Dumoulin et al. · Annals of Oncology · 2023 · 93 citations · Full text

Medicine, Oncology, Pharmacology +13

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial

Solange Peters, Byoung Chul Cho, Alexander Luft et al. · Journal of Thoracic Oncology · 2024 · 62 citations · Full text

Medicine, Oncology, Pharmacology +17

Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study.

Joel W. Neal, Farah Louise Lim, Enriqueta Felip et al. · Journal of Clinical Oncology · 2020 · 32 citations

Medicine, Oncology, Pharmacology +17